Bodycote (LSE:BOY), the Macclesfield-based heat-treatment specialist, has shown high-beta share price behaviour after a year dominated by private Capital interest. With a board-backed 940p-per-share offer from Veritas Capital agreed and CVC considering its position, bid developments have been driving the shares.
Bodycote plc has been showing high-beta characteristics. The company is the world's largest provider of heat treatment and specialist thermal processing services, treating metal components for aerospace, defence, energy, automotive and general industrial customers. It is a FTSE 250 constituent and therefore part of the FTSE All-Share.
Since May the shares have been through three Takeover episodes: an approach from Apollo that lapsed, rival proposals from CVC and Veritas, and a board-backed cash Acquisition by Veritas announced on 1 September 2026. Investors are paying attention because the shares have traded above the agreed offer value and because a competing bid remains possible, though far from certain.
Why Bodycote Is in Focus
Beta measures how much a share has moved historically relative to a benchmark. A reading above 1 implies bigger past swings than the market, in either direction; it does not predict returns. Market data showed a one-year Beta of 1.71 for Bodycote when accessed on 24 September 2026.
For Bodycote, that figure is likely to reflect company-specific jumps linked to takeover announcements rather than a stable relationship with the index. Before the approaches, the Business was already exposed to cyclical markets such as Western European automotive and general industry. Now that a deal has been agreed, daily moves are increasingly tied to the offer terms and to speculation about a rival bid.
What Does Bodycote Do?
Bodycote provides thermal processing services that improve the durability and performance of metal parts. According to the offer announcement, it runs about 130 facilities in 22 countries with around 4,000 employees. It is organised into two platforms: Specialist Technologies, including hot isostatic pressing, specialist stainless steel processes and surface technology, and Precision Heat Treatment.
Since December 2024 management has pursued an "Optimise, Perform, Grow" strategy. By 1 September, 27 of the 31 sites in the Optimise programme had been exited, including 10 automotive-focused sites in France sold in 2025. Medium-term targets included headline operating margins above 20% by 2028.
What Has Been Happening Recently?
On 22 May 2026 Bodycote confirmed a conditional proposal from Apollo following press speculation. On 5 June Apollo said it did not intend to make a firm offer, and Bodycote said it was no longer in an offer period.
On 28 July the company reported interim results in line with expectations and left its full-year outlook unchanged. On 5 August, after media speculation, it confirmed two separate conditional proposals: CVC at up to 915p and Veritas at 914p, each including the interim dividend.
On 1 September Veritas, through Vulcan Alpha Bidco, announced a board-backed cash acquisition at an offer value of 940p per share, comprising 932.8p in cash plus the 7.2p interim dividend. The same day CVC said it was "considering its position" and advised shareholders to take no action. Since then Bodycote's announcements have been dominated by Takeover Code disclosures.
What Are the Numbers Saying?
In the half year to 30 June 2026, Revenue rose 3.3% to £381.2m and adjusted operating profit increased 10.7% to £61.0m, lifting the adjusted Operating Margin to 16.0%. Core organic revenue, which excludes Non-Core sites in the Optimise programme, grew 9.6%, led by 16.7% organic growth in Specialist Technologies. Adjusted basic EPS rose 18.3% to 25.2p.
For 2025, Bodycote reported revenue of £727.1m and adjusted EBITDA of £184.7m. The Veritas offer values the fully diluted Share Capital at about £1,652m and implies an Enterprise value of about £1,852m. The cash consideration represents a 44.0% premium to the 647.8p closing price on 7 July 2026, the last business day before Veritas's initial proposal.
Why Is the Share Price Attracting Attention?
The facts: the shares traded at 951p on the morning of 1 September, above the 940p offer value. market data showed a share price of 953p on 23 September and a Market Capitalisation of about £1.61bn. Market data on 24 September showed trailing gains of 49.61% over one year and 34.32% year to date.
Possible interpretations: One possible interpretation of the shares trading above the offer value is that some Market Participants see a chance of a higher counterbid from CVC, which has made no firm offer. Another is that event-driven funds are active, consistent with the Volume of Form 8.3 disclosures. Some investors may view the current beta as a record of discrete bid-related jumps, making it a less useful guide while the offer is pending.
How Does the FTSE All-Share Context Matter?
Bodycote sits in the FTSE 250 and therefore the FTSE All-Share, the broad measure of the UK market. Its share-price path this year has followed takeover announcements rather than index direction, and there is no evidence that index moves caused its recent swings. FTSE 250 tracker funds, which market data shows among its holders, would be affected if the company is taken private and delisted.
The deal also fits a wider pattern of private capital interest in UK-listed industrial companies, with each completed take-private removing a constituent from the All-Share.
What Could Investors Watch Next?
Factual items that could influence sentiment include:
- Scheme document: due to be sent within 28 days of 1 September, followed by court and general meetings.
- CVC's position: whether CVC announces a firm competing offer or steps back.
- Interim dividend: the 7.2p payment is expected on 5 November 2026 to shareholders on the register on 2 October 2026.
- Completion timetable: the acquisition is expected to become effective in the first quarter of 2027, subject to conditions including regulatory approvals.
- Trading: management expects revenue growth to moderate in the second half against prior-year comparisons.
The Bottom Line
Bodycote (LSE:BOY) has been showing high-beta characteristics after a year of takeover activity that repeatedly moved the shares. Apollo stepped away in June, CVC and Veritas made competing proposals in August, and the board backed Veritas's 940p offer on 1 September. The high historical beta largely reflects these company-specific events, and beta describes past Volatility rather than future returns. What matters next is the scheme document and Shareholder votes, whether CVC returns with a firm offer, and whether conditions are met on the timetable to completion in early 2027.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...